AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.

Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M
Cell Metab. 2011 13 (4): 376-388

PMID: 21459323 · PMCID: PMC3086578 · DOI:10.1016/j.cmet.2011.03.009

AMPK has emerged as a critical mechanism for salutary effects of polyphenols on lipid metabolic disorders in type 1 and type 2 diabetes. Here we demonstrate that AMPK interacts with and directly phosphorylates sterol regulatory element binding proteins (SREBP-1c and -2). Ser372 phosphorylation of SREBP-1c by AMPK is necessary for inhibition of proteolytic processing and transcriptional activity of SREBP-1c in response to polyphenols and metformin. AMPK stimulates Ser372 phosphorylation, suppresses SREBP-1c cleavage and nuclear translocation, and represses SREBP-1c target gene expression in hepatocytes exposed to high glucose, leading to reduced lipogenesis and lipid accumulation. Hepatic activation of AMPK by the synthetic polyphenol S17834 protects against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in diet-induced insulin-resistant LDL receptor-deficient mice in part through phosphorylation of SREBP-1c Ser372 and suppression of SREBP-1c- and -2-dependent lipogenesis. AMPK-dependent phosphorylation of SREBP may offer therapeutic strategies to combat insulin resistance, dyslipidemia, and atherosclerosis.

Copyright © 2011 Elsevier Inc. All rights reserved.

MeSH Terms (18)

AMP-Activated Protein Kinases Animals Atherosclerosis Benzopyrans Dietary Fats Disease Models, Animal Fatty Liver Humans Insulin Resistance Lipogenesis Male Metformin Mice Phosphorylation Receptors, LDL Sterol Regulatory Element Binding Protein 1 Sterol Regulatory Element Binding Protein 2 Transcription, Genetic

Connections (1)

This publication is referenced by other Labnodes entities:

Links